Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NOS2 | P35228 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | HTR5A | P47898 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | RAD52 | P43351 | 1/20 | 0.31 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.31 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29789697 | 0.79 | MAPT (0.50) | GAAMAPTNOS2ALDH1A1CYP3A4 | |
| SCHEMBL2255782 | 0.79 | MAPT (0.50) | GAAMAPTNOS2ALDH1A1CYP3A4 | |
| SCHEMBL21145451 | 0.76 | GAA (0.46) | GAAMAPTNOS2ALDH1A1CYP3A4 | |
| SCHEMBL1285713 | 0.76 | MAPT (0.46) | GAAMAPTNOS2ALDH1A1CYP3A4 | |
| SCHEMBL6607968 | 0.76 | GAA (0.46) | GAAMAPTNOS2ALDH1A1CYP3A4 | |
| SCHEMBL29274483 | 0.76 | KDM4E (0.36) | GAAMAPTTDP1KDM4EMEN1 | |
| SCHEMBL5910616 | 0.76 | KDM4E (0.33) | GAAMAPTTDP1KDM4EMEN1 | |
| SCHEMBL2125224 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL29976025 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 | |
| SCHEMBL11026821 | 0.73 | GAA (0.43) | GAAMAPTALDH1A1CYP3A4HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461346-B2 | Benzyl amines, a process for their production and their use as anti-inflammatory agents | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2013-06-11 | — | — | US | disclosed |
| US-20120289510-A1 | Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents | ASTRAZENECA AB (SE) | 2012-11-15 | — | — | US | disclosed |
| WO-2012025578-A3 | AN APPLICATOR FOR APPLYING A COSMETIC COMPOSITION AND A COSMETIC PACKAGING INCLUDING SUCH AN APPLICATOR | ALBEA SERVICES (FR) | 2012-05-10 | — | — | WO | disclosed |
| US-8173676-B2 | Benzyl, amines, a process for their production and their use as anti-inflammatory agents | Bayer Pharma AG (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-2041069-B1 | BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Pharma AG (DE) | 2011-11-30 | — | — | EP | disclosed |
| US-7999108-B2 | Benzyl amines, a process for their production and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AG (DE) | 2011-08-16 | — | — | US | disclosed |
| EP-2041069-A1 | BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-04-01 | — | — | EP | disclosed |
| US-20080032986-A1 | BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2008-02-07 | — | — | US | disclosed |
| WO-2008006627-A1 | BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-01-17 | — | — | WO | disclosed |
| EP-1878717-A1 | Benzyl amines, a process for their production and their use as anti-inflammatory agents | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-01-16 | — | — | EP | disclosed |
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | AGOURON PHARMACEUTICALS, LLC | 2004-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171634-A1 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use | CDK3, BRAF, ROCK1 | GAA 2420/4885MAPT 812/4885NOS2 193/4885 |
| US-20080032986-A1 | BENZYL AMINES, A PROCESS FOR THEIR PRODUCTION AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | IL1B, BBOX1, TNF | GAA 808/4885MAPT 2023/4885NOS2 7/4885 |
| US-20120289510-A1 | Benzyl Amines, A Process For Their Production And Their Use As Anti-Inflammtory Agents | IL1B, TNF, NFKBIA | GAA 1186/4885MAPT 1595/4885NOS2 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.